Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua W D Tobin

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Blood|April 30, 2026
SIGN of the times: DC-SIGN and the follicular lymphoma nicheJoshua W D Tobin, Maher K Gandhi
Blood|May 27, 2021
Discordant solutions to discordant problemsJoshua W D Tobin, Maher K Gandhi
American Journal of Hematology|October 8, 2020
Risk-adapted therapy in follicular lymphoma: Is it time to "FLEX"?Joshua W D Tobin, Maher K Gandhi
Cells|June 2, 2021
PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell LymphomaJoshua W D Tobin, Karolina Bednarska, Ashlea Campbell, et al.
Cancer Immunology Research|November 3, 2022
The PO4-tential for Less Toxic CAR T-cell TherapiesJoshua W D Tobin, Michael R Green, Maher K Gandhi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2019
Reply to M. SorigueJoshua W D Tobin, Colm Keane, Jay Gunawardana, et al.
Ejhaem|February 13, 2025
An Economic Evaluation of the TROG 99.03 Trial: Systemic Therapy After Radiotherapy in Early-Stage Follicular LymphomaDaniel Erku, Joshua W D Tobin, John F Seymour, et al.
Leukemia & Lymphoma|July 29, 2021
A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphomaJoshua W D Tobin, Anna Crothers, Ti Eric Ma, et al.
British Journal of Haematology|December 29, 2023
Epstein-Barr virus-associated lymphomas decodedKarolina Bednarska, Rakin Chowdhury, Joshua W D Tobin, et al.
Ejhaem|July 18, 2022
Genetic aberrations of <i>NLRC5</i> are associated with downregulated MHC-I antigen presentation and impaired T-cell immunity in follicular lymphomaJay Gunawardana, Justina N Lee, Karolina Bednarska, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Blood|April 30, 2026
SIGN of the times: DC-SIGN and the follicular lymphoma nicheJoshua W D Tobin, Maher K Gandhi
Blood|May 27, 2021
Discordant solutions to discordant problemsJoshua W D Tobin, Maher K Gandhi
American Journal of Hematology|October 8, 2020
Risk-adapted therapy in follicular lymphoma: Is it time to "FLEX"?Joshua W D Tobin, Maher K Gandhi
Cells|June 2, 2021
PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell LymphomaJoshua W D Tobin, Karolina Bednarska, Ashlea Campbell, et al.
Cancer Immunology Research|November 3, 2022
The PO4-tential for Less Toxic CAR T-cell TherapiesJoshua W D Tobin, Michael R Green, Maher K Gandhi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2019
Reply to M. SorigueJoshua W D Tobin, Colm Keane, Jay Gunawardana, et al.
Ejhaem|February 13, 2025
An Economic Evaluation of the TROG 99.03 Trial: Systemic Therapy After Radiotherapy in Early-Stage Follicular LymphomaDaniel Erku, Joshua W D Tobin, John F Seymour, et al.
Leukemia & Lymphoma|July 29, 2021
A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphomaJoshua W D Tobin, Anna Crothers, Ti Eric Ma, et al.
British Journal of Haematology|December 29, 2023
Epstein-Barr virus-associated lymphomas decodedKarolina Bednarska, Rakin Chowdhury, Joshua W D Tobin, et al.
Ejhaem|July 18, 2022
Genetic aberrations of <i>NLRC5</i> are associated with downregulated MHC-I antigen presentation and impaired T-cell immunity in follicular lymphomaJay Gunawardana, Justina N Lee, Karolina Bednarska, et al.
Pageof 3